Oncology & Cancer

GIST tumors linked to NF1 mutations, genetic testing needed

Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel, called the duodenal-jejunal ...

Oncology & Cancer

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Oncology & Cancer

New drug overcomes resistance in patients with rare sarcoma

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report ...

Medications

Predicting correct dosage may improve success of drug repurposing

Before a drug can be used to treat a disease, it must go through a lengthy and expensive trial process to prove both safety and effectiveness. By repurposing already-approved drugs, researchers can cut out the time and expense ...

Medications

FDA expands approval of Bayer cancer drug (Update)

The U.S. Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that do not respond to other treatments.

page 2 from 4